Back to Search
Start Over
Assessment of potential drug-drug interactions in hospitalized patients with infectious diseases: an experience from a secondary care hospital [version 3; peer review: 1 approved, 2 not approved]
- Source :
- F1000Research. 13:164
- Publication Year :
- 2024
- Publisher :
- London, UK: F1000 Research Limited, 2024.
-
Abstract
- Background Polypharmacy is common among hospitalized patients with infectious infections owing to comorbidities or concomitant illnesses. This raises the likelihood of drug-drug interactions and creates uncertainty for healthcare providers. This study aimed to assess the potential drug-drug interactions (pDDIs) among hospitalized patients with infectious diseases in a secondary care hospital. Methods A prospective observational study was conducted in the internal medicine ward for six months after the ethics committee’s approval. Data were collected from patient case records, and prescriptions were screened for pDDIs from a portable electronic physician information database (PEPID) resource analyzed using SPSS, version 27.0. Results In total, 148 patient case records were analyzed, and 549 pDDIs were identified, with 66.8% having at least one or more DDIs. The mean number of drug interactions was 3.70 ± 4.58 per prescription. The most frequently encountered drug interactions were drug combinations such as bisoprolol with atorvastatin and aspirin with tazobactam/piperacillin. Bivariate analysis showed that age, comorbidities, length of hospital stay, and the number of drugs prescribed were risk factors associated with DDIs (p Conclusions This study observed the prevalence of DDIs in hospitalized patients with infectious diseases of ‘moderate’ severity. Prescription screening using a drug information database assists in early identification and prevention of DDIs, enhancing drug safety and quality of patient-centered care.
Details
- ISSN :
- 20461402
- Volume :
- 13
- Database :
- F1000Research
- Journal :
- F1000Research
- Notes :
- Revised Amendments from Version 2 We have made numerous significant changes in this updated version in response to the reviewers' feedback. To ensure correct attribution and clarity, we first included citations for the introduction's definitions of drug-drug interactions (DDIs). We cited pertinent research to back up our assertions about how age and polypharmacy affect DDIs. To improve regulatory context, we also referenced the European Medicines Agency Guidelines in the methodology section. To help readers comprehend, we defined pharmacokinetic and pharmacodynamic interactions and explained the timing and methodology of covariate selection, emphasising that it was done a priori. In addition, we made sure that a comparison of patient age groups was included, re-examined the use of median and interquartile range (IQR) for demographic data, and highlighted the occurrence of potentially hazardous drug-drug interactions (pDDIs) in the Results section. Along with removing Table 3 from the text and adding the required citations to the discussion—especially with relation to cautious prescribing practices and the healthcare implications for ageing populations—we also clarified the average number of drugs per prescription. To improve consistency, grammatical errors were fixed, an irrelevant sentence was eliminated, and the percentage of patients with pDDIs was added to Table 1. In order to present a fair assessment of our findings, we concluded by included a section on our study's advantages. All of these changes improve the manuscript's rigour and clarity., , [version 3; peer review: 1 approved, 2 not approved]
- Publication Type :
- Academic Journal
- Accession number :
- edsfor.10.12688.f1000research.143186.3
- Document Type :
- research-article
- Full Text :
- https://doi.org/10.12688/f1000research.143186.3